MedPath

Extracorporeal Shockwave Therapy for the Treatment of Refractory Chronic Angina Pectoris

Phase 1
Conditions
Refractory Angina Pectoris
Interventions
Device: Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
Registration Number
NCT01567644
Lead Sponsor
Medispec
Brief Summary

Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones.

The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with refractory angina not amenable to revascularization with angioplasty or bypass surgery.

Detailed Description

Low intensity shockwaves (1/10 the ones used in Lithotripsy) are delivered to myocardial ischemic tissue. Shockwaves are created by a special generator and are focused using a shockwave applicator device. The treatment is guided by standard echocardiography equipment. The shockwaves are delivered in synchronization with Patient R-wave to avoid arrhythmias. The treatment is painless.

At first, the patient undergoes stress- PET testing to identify the ischemic areas. Following that, the same area is localized by the ultra-sound device and the shockwaves are focused to the ischemic area. Several treatments are required for optimal results.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
35
Inclusion Criteria
  • Diagnosed with chronic stable angina pectoris.
  • Documented myocardial segments with reversible ischemia
  • AP CCS class of III-IV.
  • Stable dosage of medication used to treat angina for at least 6 weeks prior to enrollment.
  • Exercise tolerance time < 10 min (modified Bruce)
  • Two ETT tests results (within two weeks) averaging no more than 25% of their mean
  • Documented epicardial coronary artery disease not amenable to angioplasty or CABG.
  • Signed an IRB approved informed consent form.
  • Life expectancy of > 12 months.
Exclusion Criteria
  • Intraventricular thrombus
  • Malignancy in the area of treatment
  • Severe COPD
  • No smoking during the study procedure
  • MI less < 3 months prior to treatment
  • Severe Valvular disease
  • Child bearing potential

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Active Shockwave TherapyCardiac Extracorporeal Shockwave Therapy generator (Cardiospec)Patients in this group receive shockwave therapy.
Primary Outcome Measures
NameTimeMethod
Change in AP-CCS6 Months

The AP CCS Stage at the 6 months post baseline.

Secondary Outcome Measures
NameTimeMethod
Exercise tolerance time6 Months

The change in Total Exercise Time (Exercise Tolerance Test-ETT) from baseline to 6 months post baseline

Change in PET scan6 months

The change in perfusion in pharmacological induced stress PET scan (at rest and at stress) from baseline to 6 months post baseline.

Trial Locations

Locations (1)

Heart and Diabetes Center North-Rhine Westfalia

🇩🇪

Bad Oeynhausen, Germany

© Copyright 2025. All Rights Reserved by MedPath